Dysregulation of cellular signaling pathways can lead to colon cancer. However, research on the key signaling effectors or regulators in colon carcinogenesis is limited. Casein kinase-2 interacting protein-1 (CKIP-1; also known as PLEKHO1) is crucial during adult bone formation and is a promising drug target for osteoporosis therapy. In this study, we observed that CKIP-1 was downregulated in human colon cancer tissues and colon cancer cell lines, and this result was correlated with colon cancer progression. CKIP-1 silencing in colon cancers involved promoter methylation. In colon cancer HCT116 and SW480 cells, CKIP-1 overexpression inhibited cell growth and migration. CKIP-1 also suppressed in-vivo tumor formation. Notably, the growthsuppressive role of CKIP-1 was dependent on the downregulation of the cell cycle-regulated oncogene Smad ubiquitylation regulatory factor-1 (Smurf1). During cell cycle progression, phosphatidylinositol-3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) signaling increased Smurf1 production by an mTOR-dependent translational control mechanism. Rapamycin, the mTOR inhibitor, significantly reduced Smurf1 protein levels, and Smurf1 was degraded in mitosis. In colon cancer, CKIP-1 controlled Smurf1 expression by suppressing PI3K/Akt/mTOR signaling and enhancing Smurf1 autodegradation, and CKIP-1 downregulation was correlated with Smurf1 upregulation in colon carcinogenesis. These findings provide novel insight into the mechanisms of the candidate tumor suppressor CKIP-1.
INTRODUCTION
The pleckstrin homology domain-containing protein casein kinase-2 interacting protein-1 (CKIP-1; also known as PLEKHO1) was originally reported to specifically interact with the casein kinase-2 (CK2) a-subunit but not the a'-subunit. 1 Subsequently, a number of studies indicated that CKIP-1 is a scaffold protein that mediates interactions with multiple proteins, including CK2a, CPa, AP-1/c-Jun, Akt, ATM, IFP35/Nmi and Smurf1 (Smad ubiquitylation regulatory factor-1). [1] [2] [3] [4] [5] [6] [7] The CKIP-1 knock-out mice model has shown that CKIP-1 is a negative regulator of bone formation but not bone resorption. 5 Recently, the (AspSerSer) 6 -liposome system was used to deliver CKIP-1 small interfering RNAs selectively to bone-formation surfaces. 8 CKIP-1 knockdown successfully promoted bone formation in healthy and osteoporotic rats without activating resorption, suggesting that CKIP-1 is a potential target for the treatment of bone diseases, such as osteoporosis. CKIP-1 inhibits osteoblast differentiation and bone formation by enhancing the ubiquitin ligase activity of Smurf1 and then terminating bone morphogenetic protein (BMP) signaling. 5 In addition, CKIP-1 could interact with Akt and inhibit Akt kinase activity. 7 CKIP-1 suppresses fibrosarcoma cell survival, possibly by downregulating phosphatidylinositol-3-kinase (PI3K)/Akt signaling. The growth of stable CKIP-1 transfectants xenografted into nude mice was slower than that of mock transfectants. These findings indicate that CKIP-1 would be a candidate of tumor suppressor with an Akt inhibitory function. 7 However, the underlying mechanisms of CKIP-1 in tumor cell growth, especially the molecular events downstream of Akt, remain poorly understood. In addition, the suggested tumor suppressive role of CKIP-1 has been only investigated in cultured cell lines and nude mice. The clinical association of CKIP-1 in tumor development is still unclear.
Colon cancer is the third most common cancer and second leading cause of cancer-related deaths worldwide. 9 The lack of effective early detection and poor prognosis lead to the low survival rate of colon cancer patients. Colon cancer experiences a multi-step process, with both genetic and epigenetic alterations in a sequential order. It has been recognized that, adenomatous polyposis coli (APC) gene inactivation caused the initial appearance of the adenoma, KRAS mutations or other genetic alterations (such as deletion on chromosome 18q), which led to the growth and progression of adenoma, and p53 inactivation resulted in the adenoma-to-carcinoma transition. Exploring the mechanisms of colon carcinogenesis has been the major topic in recent years. Large observations have indicated that the aberrant activation of pathways, such as Wnt/b-catenin signaling, PI3K/Akt signaling and inactivation of transforming growth factor-b (TGFb)/Smads signaling contributed to the initiation and progression of colon cancer. The mutation and dysregulation of components, including epidermal growth factor receptor (EGFR), PI3K, Akt, mammalian target of rapamycin (mTOR), TGFbR, Smad4, adenomatous polyposis coli, Axin and b-catenin, are wellrecognized causes of signaling abnormalities that result in cancer. [10] [11] [12] [13] [14] In this study, we explored the effect of CKIP-1 on colon cancer cells in vitro and in vivo, and we investigated the molecular mechanisms behind the growth-suppressive activity of CKIP-1 in colon cancer cells. Here we provide the first clinical significance for CKIP-1 in colon cancer detection.
RESULTS

CKIP-1 acts as a candidate tumor suppressor in colon cancer
To explore the possible role of CKIP-1 in colon cancer development, we collected 45 pairs of patient colon cancer tissues and adjacent normal mucosa tissues, which were verified by hematoxylin and eosin staining (Supplementary Figure 1) . By immunoblotting and immunohistochemistry analysis, we found that the CKIP-1 protein was significantly decreased in 28 out of 45 (B62%) tumor samples, compared with the adjacent normal mucosa (Figure 1a ), and the representative samples for immunoblotting and immunohistochemistry analysis are shown in Figures 1b-c. Similar to protein levels, the CKIP-1 mRNA level was also reduced in colon cancer tissues ( Figure 1a) . Moreover, the CKIP-1 expression level was lower universally in the colon cancer cell lines compared with that of the normal mucosa cells (Figure 1d ). Among the colon cancer cell lines, CKIP-1 was moderately expressed in HCT116 and SW480 cells, whereas lowly expressed in others we examined (Figure 1d ). These results suggest that the downregulation of CKIP-1 might be relevant to human colon cancer development.
The repressed CKIP-1 expression in colon cancer inspired us to investigate whether CKIP-1 functions as a candidate tumor suppressor. In HCT116 and SW480 cells, G418-selected stable overexpression of CKIP-1 suppressed colony formation compared with the control cells (Figure 1e ). In addition, using the lentivirus system we observed that CKIP-1-overexpressing HCT116 and SW480 cells exhibited reduced cell viability (Figure 1f) . Conversely, CKIP-1 short hairpin RNA (shRNA) lentivirus-infected HCT116 cells and SW480 cells showed increased cell growth (Figure 1g ). The knockdown efficiency of CKIP-1 was verified by both immunoblotting and quantitative reverse transcriptase-PCR (qRT-PCR) analysis (Figure 1h ). To further investigate the suppression of cell viability, we determined the effect of CKIP-1 on cell cycle progression; CKIP-1 had little effect on apoptosis in colon cancer cells (data not shown). CKIP-1 blocked cell cycle progression when colon cancer HCT116 and SW480 cells were synchronized by nocodazole treatment at the G2/M transition (Figure 1i ). In addition, we assayed CKIP-1 effects on colon cancer cell motility, with a cell migration and invasion assay. As shown in Figures 1j and k, CKIP-1 overexpression effectively inhibited colon cancer cell migration and invasion in HCT116 cells.
To identify potential tumor suppression in vivo, we evaluated the effect of CKIP-1 restoration on the tumorigenicity and growth of colon cancer cells in nude mice. The injection of CKIP-1 shRNA lentivirus-infected colon cancer cell line HCT116 resulted in accelerated tumor formation and a dramatic increase in tumor size compared with the control transfectants (Figures 1l and m) . Conversely, CKIP-1 overexpression suppressed tumor formation and decreased the tumor size (Figures 1l and m) . These results suggested that CKIP-1 acted as a tumor suppressor for colon cancer.
CKIP-1 is silenced by a promoter hypermethylation in colon cancer and correlates with cancer progression To gain insight into CKIP-1 depression in colon cancer, we determined whether promoter methylation was involved, as the CKIP-1 promoter is rich in CpG islands (Supplementary Figure 2) . As shown in Figure 2a , treatment with 5-Aza, a DNA methyltransferase inhibitor, increased CKIP-1 expression in multiple colon cancer cell lines, including HCT116, HCT15 and SW480 (Figure 2a) . To clarify the methylation status of the CKIP-1 promoter, we performed methylation-specific PCR analysis in both colon cancer cell lines and human colon cancer samples. In normal colon mucosa, the CKIP-1 promoter was unmethylated, whereas in human colon cancer tissues and cell lines, the CKIP-1 promoter was partially methylated (Figure 2b ). These findings suggested that methylation of the CKIP-1 promoter reduces its expression in colon cancer.
To investigate the expression feature and clinical significance of CKIP-1 in colon cancer development, we measured the correlation between downregulated CKIP-1 and cancer progression in colonic adenoma and carcinoma patients. Spearman's rank correlation analysis identified a significant correlation between CKIP-1 reduction in tissues and the progression of colonic adenoma and carcinoma from stage I to IV in samples tested (Figure 2c ). CKIP-1 promoter methylation was also associated with colon cancer progression (Figure 2d ).
CKIP-1 expression is inversely correlated with Smurf1 in colon cancer It has been reported that CKIP-1 suppresses PI3K/Akt and BMP signaling transduction. 5, 7 However, the detailed mechanisms of CKIP-1 action in tumor cell growth are unclear. CKIP-1 promotes the self-ubiquitylation and autodegradation of the ubiquitin ligase Smurf1 by enhancing its ligase activity and coupling with the 26S proteasome ATPase subunit Rpt6. 5, 15 In addition to autodegradation, Smurf1 controls the ubiquitylation and degradation of numerous substrates and has key roles in proliferation, apoptosis, polarization and bone homeostasis. [16] [17] [18] Notably, Smurf1 is a potential amplification target in pancreatic cancer cells, and it is highly expressed in colon cancer, esophageal squamous carcinoma and pancreatic cancer. 19, 20 However, the potential functional relevance between CKIP-1 and Smurf1 during carcinogenesis is unknown. 
Novel mechanisms of CKIP-1 in tumor suppression J Nie et al In HCT116 and SW480 cells, endogenous Smurf1 levels were decreased in a dose-dependent manner when CKIP-1 was overexpressed ( Figure 3a) . Conversely, Smurf1 expression was upregulated after CKIP-1 depletion by lentivirus shRNA-mediated knockdown ( Figure 3b ). In the 16 cases of human colon cancer samples displayed in Figure 3c , CKIP-1 was downregulated in 10 out of 16 tumor tissues compared with matched normal tissues (numbers 2-7, 9, 11, 15 and 16), among which concurrent CKIP-1 low expression and Smurf1 high expression occurred in 7 out of 10 samples (numbers 2, 3, 5-7, 11, 16; Figure 3c ). Thus, Smurf1 and CKIP-1 expressions were inversely correlated in colon cancer samples ( Figure 3d ).
Colon cancer originates from crypt stem cells, and it has been recognized that the genetic and epigenetic alterations cause the growth and progression of adenoma, and ultimately carcinoma. By immunohistochemistry analysis, we observed that CKIP-1 was expressed extensively in the normal colonic crypt epithelial cells, and the expression was partially decreased at the bottom of the crypt where the crypt stem cells located (Figure 3e ). Strikingly, in colon cancer tissues, the CKIP-1 level was much lower compared with that of the normal mucosa. Conversely, Smurf1 was highly expressed in colon cancers tissues, whereas it was lowly expressed in the normal tissue. By continuous slicing and immunohistochemical staining, we confirmed the inverse correlation between CKIP-1 and Smurf1 expression in both normal and tumor tissues ( Figure 3e ). Moreover, in normal colonic epithelial NCM460 cells, overexpression of exogenous CKIP-1 downregulated the Smurf1 levels, whereas depletion of endogenous CKIP-1 upregulated the Smurf1 levels ( Figure 3f ). Taken together, CKIP-1 distribution and expression changed during the transition from stem cells to the differentiated cells, which might contribute to the alteration of Smurf1 protein level and the progression of colon cancer.
CKIP-1 regulates cell growth by targeting the oncogene Smurf1
Next we investigated whether the CKIP-1-mediated growthsuppressive effect depended on Smurf1 inhibition. By using the CCK-8 (Cell Counting Kit 8) assay, we tested whether Smurf1 was required for CKIP-1-mediated growth suppression. As shown in Figure 4a , CKIP-1 failed to regulate cell growth when Smurf1 was knocked down in HCT116 and SW480 cells. In addition, CKIP-1 expression did not inhibit the migration of colon cancer cells in the absence of endogenous Smurf1 (Figure 4b ), confirming our hypothesis that CKIP-1 negatively regulates colon cancer cell growth and migration by downregulating Smurf1. In colon cancer cells, CKIP-1 overexpression enhanced Smurf1 E3 ligase activity and promoted the Smurf1 autodegradation, as well as the degradation of its substrate RhoA (Figure 4c ). In addition, the E3 ligase activity of Smurf1 was necessary for its oncogenic ability and the CKIP-1 tumor-suppressive role, because that infection of Smurf1 WT-res (which had no interaction with CKIP-1, but with wild-type E3 ligase activity) can reverse the growth-suppressive effects; whereas Smurf1 CA (E3 ligase activity-defective C699A mutant) had no such ability ( Figure 4d ).
Furthermore, we investigated the importance of CKIP-1 and Smurf1 in colon carcinogenesis. As shown, knockdown of CKIP-1 or overexpression of Smurf1 was able to enhance cell growth of normal colonic epithelial NCM460 cells (Figure 4e ). The ability of anchorage-independent growth is a specialty for malignantly transformed cells. The soft-agar colony-formation assays showed that the NCM460 cells infected with lentivirus carrying CKIP-1 shRNA (to knockdown CKIP-1 expression) or Smurf1 construct (to overexpress Smurf1) resulted in the formation of transformed colonies ( Figure 4f ). Correspondingly, overexpression of CKIP-1 or depletion of Smurf1 in HCT116 cells significantly inhibited the colony formation in the soft-agar medium (Figure 4g ). These results indicated that CKIP-1 downregulation or Smurf1 upregulation might be the candidate oncogenic factors in colon cancer development.
CKIP-1 inhibits the mTOR-mediated translational control of Smurf1 As CKIP-1 was involved in cell cycle progression (Figure 1i ), we investigated whether Smurf1 participated in cell cycle control. First, we detected Smurf1 expression in colon cancer cell cycle N7  N6  N5  N4  N3  N2  N1  IVD   T7  T6  T5  T4  T3  T2  T1 Novel mechanisms of CKIP-1 in tumor suppression J Nie et al progression using a double thymidine protocol. More than 90% of HCT116 cells were arrested in the G1 phase and nocodazole treatment synchronized cells at the prometaphase. To evaluate the mitotic progression, we monitored the levels of two marker proteins, cyclin B1 and phosphorylated histone H3. As shown in Figure 5a , cyclin B1 and phosphorylated histone H3 levels increased 10 h after thymidine release into nocodazole (left panel), which began to decline after nocodazole release (right panel), reflecting mitotic exit. Notably, the Smurf1 expression increased during cell cycle progression to its maximum level at 10 h after the thymidine release, when most cells were in the G2/ M transition ( Next we investigated the mechanism of cell cycle-dependent Smurf1 variation. Given that the Smurf1 mRNA level was unchanged after release from synchronization (Figure 5e ), the variable expression of Smurf1 during the cell cycle could be due to protein synthesis or degradation. We observed that CKIP-1 expression remained unchanged during the cell cycle progression ( Figure 5a) ; thus, CKIP-1 might not directly regulate Smurf1 protein level during cell cycle. The mTOR, which is a Ser/Thr kinase, has a crucial role in protein translation control. 13 Rapamycin inhibited the production of endogenous but not exogenous Smurf1 protein (Figure 5f ), indicating that Smurf1 translation was mTORdependent. In addition, we observed that the cell cycle-related fluctuation of Smurf1 expression was dramatically suppressed when cells were treated with the PI3K inhibitor LY294002 but not with the TGF-b receptor inhibitor A83-01 (Supplementary Figure 4a) . Furthermore, p38 mitogen-activated protein kinase or ERK inhibitors (SB239063 and PD98059, respectively) had no or slight influence on Smurf1 fluctuation during the cell cycle (Supplementary Figure 4b) , suggesting that Smurf1 expression was specifically regulated by PI3K/mTOR signaling.
Rapamycin treatment suppressed the cell cycle-regulated induction of Smurf1 expression but had no effect on its close homologue Smurf2 (Figures 5f and g ); this result confirmed the crucial role of mTOR signaling in Smurf1 expression. To investigate the role of EGF/PI3K/mTOR signaling on Smurf1 expression, we evaluated the influence of EGF on Smurf1 protein levels. As shown in Figure 5h , EGF stimulated Akt phosphorylation in HCT116 and SW480 cells. Endogenous Smurf1 increased when cells were treated with EGF, but its levels dramatically decreased when the inhibitors LY294002 or rapamycin were added in combination with EGF (Figure 5h ). This effect was specific for Smurf1, because Smurf2 had no such change after EGF stimulation and PI3K/mTOR inhibition. These results demonstrated that Smurf1 expression changed during cell cycle progression and that the mTOR pathway controlled Smurf1 translation. As reported previously, CKIP-1 interacts with Akt, inhibits Akt phosphorylation and negatively regulates the PI3K/Akt pathway in breast cancer cells. 7 On the basis of the decreased phosphorylation of Akt and GSK3b (glycogen synthase kinase-3b; a downstream target of Akt), we found that CKIP-1 suppressed Akt activity in colon cancer HCT116 and SW480 cells, accompanied by Smurf1 reduction (Figure 5i) . Thus, the negative regulation of Smurf1 by CKIP-1 during cell cycle might be due to the inhibition of Akt. We determined the effect of CKIP-1 in the presence of PI3K signaling inhibitors. Similar to PI3K/ mTOR inhibitors (rapamycin and LY294002), CKIP-1 overexpression inhibited the EGF-mediated induction of Smurf1 ( Figure 5j) ; however, CKIP-1 failed to negatively regulate Smurf1 expression when cells were treated with rapamycin or LY294002. These results suggested that EGF/PI3K/Akt/mTOR signaling is central to Smurf1 upregulation during the cell cycle and that CKIP-1 controls Smurf1 expression by opposing Akt activity.
CKIP-1 enhances Smurf1 degradation during the cell cycle
In addition to the EGF-mediated increase in Smurf1, the ubiquitinproteasome system regulated Smurf1 expression, as Smurf1 was not decreased in M phase after treatment with MG132, the 26S proteasome inhibitor (Figure 6a) . Moreover, the in-vivo ubiquitylation assay indicated that Smurf1 ubiquitylation was significantly enhanced in mitosis (Figure 6b) , which correlated to the low expression of Smurf1 in that stage (Figure 5a and Figure 6a ). To further define the factors controlling Smurf1 degradation, we examined the effects of depletion of the three major negative regulators of Smurf1, that is, FBXL15, CDH1 and CKIP-1.
5,21,22
Smurf1 expression levels reduced at M phase and recovered only when CKIP-1 was knocked down (Figure 6c ), revealing that CKIP-1, but not FBXL15 and CDH1, is important for controlling Smurf1 expression during the cell cycle. In addition, the restoration of CKIP-1 significantly enhanced the ubiquitylation of Smurf1 in colon cancer HCT116 cells (Figure 6d ). Although Akt activity was crucial for Smurf1 induction during the cell cycle, it could not affect the polyubiquitylation and degradation of Smurf1 in mitosis (Figures 6d and e) . As CKIP-1 can bind to and enhance the autodegradation of Smurf1, 5 we next detected the interaction between Smurf1 and CKIP-1 in mitosis. To prevent the degradation of Smurf1 by CKIP-1, we used Smurf1 C699A (CA) and CKIP-1 in the coimmunoprecipitation assay. As shown in Figure 6f , the interaction between CKIP-1 and Smurf1 was dramatically increased in mitosis, which was in accordance to the enhanced ubiquitylation and degradation of Smurf1 in that cell phase (Figures 6a and b) .
Taken together, these data indicate that Smurf1 has a crucial role in the cell cycle progression, whereas CKIP-1 controls colon cell proliferation via the negative regulation of Smurf1. The fluctuation of Smurf1 during cell cycle resulted from the balance between protein production and degradation. CKIP-1 downregulated Smurf1 expression by inhibiting its translation and promoting its degradation; therefore, CKIP-1 is a potential tumor suppressor in colon cells (Figure 6g ).
DISCUSSION
The data presented here reveal that CKIP-1 acts as a candidate of tumor suppressor in colon cancer cells. First, we showed that CKIP-1 was downregulated in various colon cancer cell lines and reduced 62% in human colon cancer tissues compared with normal mucosa tissues. The downregulation of CKIP-1 in colon cancers might be raised by the promoter methylation of the CKIP-1 gene. As far as we know, this is the first report to show the clinical role of CKIP-1 in cancer patients. Second, we showed that CKIP-1 suppressed cell growth both in vitro and in vivo. Third, we explored the downstream target of CKIP-1 in controlling colon tumorigenesis. In this regard, a previous study has identified that CKIP-1 interacts with and inhibits Akt, which contributes to the tumor-suppressive effect of CKIP-1. 7 However, the effector proteins downstream of Akt remain poorly understood. This study identified Smurf1, an HECT (homologous to E6-AP C terminus) type ubiquitin ligase that is involved in the regulation of many important proteins, as a candidate which is downstream of Akt/mTOR and required for CKIP-1 function. CKIP-1 repressed the Smurf1 synthesis and promoted Smurf1 degradation. The inhibitory role of CKIP-1 on PI3K/Akt/mTOR/Smurf1 signaling might explain the tumor suppressor function of CKIP-1.
PI3K/Akt/mTOR signaling has been well-defined to be essential for tumor cell survival. Akt-mediated activation of mTOR is critical during translation initiation. In response to stress, translational control is much faster than the regulation of mRNA synthesis and nuclear export. We have proposed an additional oncogene, Smurf1 (but not Smurf2), which acts during PI3K/mTOR signaling-mediated translational control. However, it is unclear whether the upregulation of Smurf1 in colon tumors is correlated to EGFR/ PI3K/mTOR signaling overactivation. Previously, we suggested that Smurf1 was oncogenic and associated with MDM2/p53 regulation or ING2 degradation. 20, 23, 24 Therefore, Smurf1 might be a novel oncogene involved in colon cancer development and progression.
Moreover, we demonstrated that Smurf1 was a cell cycleregulated prosurvival protein that was associated with cell cycle progression. The cell cycle program is precisely controlled, mainly through timely posttranslational protein modifications. Aberrations in cell cycle checkpoints have important roles in human carcinogenesis. Smurf2, a homolog of Smurf1, is a mitotic regulator. 25, 26 We provided strong evidence that Smurf1 expression fluctuated during the cell cycle and, consequently, influenced cell cycle progression in colon cancer. The regulation of Smurf1 degradation in specific cell cycle phase and its association with other cell cycle-related proteins need further investigation. In the current study, CKIP-1 inhibited colon tumor proliferation by suppressing the production of Smurf1 and promoting its degradation, but we cannot exclude the possibility that other targets and signaling pathways govern the CKIP-1 function during colon carcinogenesis.
We previously showed that CKIP-1 interacts with Smurf1, enhances the Smurf1-mediated substrate degradation and then inhibits bone formation. 5 In the context of bone formation control, CKIP-1 functions as an activator of Smurf1. Here we suggested that in the context of tumor cell proliferation, CKIP-1 functions as an inhibitor of Smurf1. CKIP-1 promotes the self-ubiquitylation and autodegradation of Smurf1. This resulted in the inverse correlation between CKIP-1 and Smurf1 protein levels in colon cancer samples.
Our study implicates the diversity and complexity of colon carcinogenetic signaling. We suggested the crosstalk between the PI3K/mTOR and TGF-b/BMP pathways. TGF-b family members modulate numerous diverse signaling pathways utilizing distinct effectors. For instance, TGF-b induces PI3K signaling during the epithelial to mesenchymal cell transition. 27 Smurf1 is a major negative regulator of TGF-b/BMP signaling via the ubiquitylation and degradation of Smad proteins. Here we revealed Smurf1 activation in response to EGF treatment or Akt overexpression in colon cancer cells, suggesting the potential inverse correlation between PI3K and TGF-b/BMP signaling. Furthermore, the aberrant activation of PI3K/mTOR signaling might induce Smurf1 expression, leading to a repression of TGF-b/ BMP-stimulated growth suppression.
In summary, the current study suggests that CKIP-1 is a potential tumor suppressor and scaffold molecule that may modify and regulate the activities of several signaling pathways, including PI3K/mTOR and TGF-b/BMP.
MATERIALS AND METHODS
Mice, cell lines and drug treatment
Balb/c athymic nude mice were obtained from the Vital River Animal Laboratories (Beijing, China). The HCT116, SW480, Caco2, HT29, HCT15 and LS174 colon cancer cell lines and human normal colonic epithelial NCM460 cells were purchased from ATCC (Rockefeller, MD, USA) and cultured in RPMI 1640 or Dulbecco's modified Eagle's medium media (Hyclone, Logan, UT, USA) containing 10% fetal bovine serum. For 5-azacytidine treatment, cells were seeded the day before the drug treatment. Cells were treated with 5 mM 5-azacytidine (Sigma, St Louis, MO, USA) for 72 h, and the medium was replaced with freshly added 5-azacytidine for every 24 h.
Patients and tissue samples
Surgically removed paired colonic adenoma and cancer tissues, and adjacent normal mucosa tissues, were collected from 60 patients at the General Hospital of PLA (Beijing, China). Surgically resected tissues were quickly stored in formalin and liquid nitrogen until analysis. The samples were used for hematoxylin and eosin staining, immunohistochemistry analysis, qRT-PCR and immunoblotting analysis. All the 45 colon cancer samples were classified by TNM staging, and included 10 cases of stage I, 13 cases of stage II, 12 cases of stage III and 10 cases of stage IV. All samples were obtained with the informed consent of the patients, and the experiments were approved by the ethics committee of General Hospital of PLA.
Antibodies and reagents
The anti-Myc antibody was purchased from BD Biosciences (San Jose, CA, USA). The anti-Flag M2, protein synthesis inhibitor cycloheximide, 5-azacytidine--2 0 -deoxycytidine, thymidine, nocodazole, PI3K inhibitor LY294002, mTOR inhibitor rapamycin and proteasome inhibitor MG132 were obtained from Sigma. The antibodies against Smurf2, Akt, phosphoAkt-S473, GSK3b, phospho-GSK3b, mTOR, phospho-mTOR, Cyclin A, Cyclin B1, Cyclin E and phospho-H3 were obtained from Cell Signaling Technology (Danvers, MA, USA). The anti-Smurf1 antibody was bought from Abcam (Cambridge, MA, USA). The anti-CKIP-1 antibody was from Abbiotec (San Diego, CA, USA). Anti-glyceraldehyde 3-phosphate dehydrogenase and secondary antibodies were produced by Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Plasmids and transfection CKIP-1 and Smurf1 expression plasmids were constructed as described previously. 5, 6 The lentiviral expression vectors for CKIP-1 or Smurf1 were constructed by inserting full-length cDNA into a pWpt vector. The lentiviral expression vector for CKIP-1 shRNA was constructed by inserting an shRNA sequence into a pSicoR vector (5 0 -TGGTCGGCTGGGTCCGGAAATTCAAGAGA TTTCCGGACCCAGCCGACCTTTTTTC-3 0 (F) and 5 0 -TCGAGAAAAAGGTCGGCT GGGTCCGGAAATCTCTTGAATTTCCGGACCCAGCCGACCA-3 0 (R)). Mammalian cells were transfected with Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. Infective lentiviruses were produced by cotransfection of the expression vector and packaging plasmids into 293FT cells, which were added to HCT116 or SW480 cells in the presence of 8 mg/ml polybrene. Immunohistochemistry CKIP-1 or Smurf1 protein expression was detected by immunohistochemical staining in colon cancer tissues and adjacent normal tissues. Briefly, the samples were fixed in formalin and embedded in paraffin. The paraffin sections were deparaffinized and subjected to a heat-induced epitope retrieval step. Endogenous peroxidase activity was blocked with 1% hydrogen peroxide in distilled water. To block nonspecific binding, the slides were incubated with 3% bovine serum albumin for 60 min at room temperature. Samples were then incubated overnight at 4 1C with primary antibody (CKIP-1, 1:300; Smurf1, 1:300). Negative controls were performed by omitting the primary antibody. For detection, specimens were sequentially incubated with secondary antibody and streptavidin-horseradish peroxidase.
Cell viability assay
Cell viability was measured using a tetrazolium salt (WST-8)-based colorimetric assay in the CCK-8. Briefly, cells were seeded on 96-well plates at an initial density of 1 Â 10 4 cells per well. At the time points indicated, spent medium was replaced with fresh medium containing 10 ml CCK-8 solution, and the plate was incubated for 50 min. Cell viability was detected by scanning with a microplate reader at 450 nm. The data were expressed as A 450 (treated or control) À A 450 (blank).
Cell cycle analysis HCT116 cells were synchronized by nocodazole treatment for 24 h before collecting. Cells were trypsinized, fixed in 70% ethanol in À 20 1C for 24 h, washed and stained with propidium iodide (0.05 mg/ml; Sigma) and RNAse A (0.1 mg/ml; Sigma) for 30 min at 37 1C. Samples were then analyzed for their DNA content by FACSCalibur from BD Biosciences.
RNA extraction and qRT-PCR
Total RNA was isolated with TRIzol reagent using to the manufacturer's instructions. Quantitative real-time PCR was carried out as described previously. 5 The Smurf1 primers were 5 0 -CTACCAGCGTTTGGATCTAT-3 ) were suspended in 0.1 ml phosphate-buffered saline and then injected subcutaneously into either side of the posterior flank of the same female BALB/c athymic nude mice at 4 weeks of age. Tumor growth was measured daily using calipers, and the tumor volume was calculated according to the formula volume ¼ length Â width 2 Â 0.5.
Immunoblotting and in-vivo ubiquitylation assays
The lysed protein extracts were subjected to SDS-polyacrylamide gel electrophoresis, transferred onto nitrocellulose membranes and then immunostained, as described previously. 23, 24 For in-vivo ubiquitylation assays, cells were treated with MG132 (50 mM; Sigma) before they were collected, and they were lysed in modified RIPA lysis buffer (10 mM Tris-HCl (pH 7.5), 150 mM NaCl, 5 mM EDTA, 1% (v/v) NP-40, 1% sodium deoxycholate, 0.025% SDS, 1 Â protease inhibitors). Proteins in the lysates were immunoprecipitated with the indicated antibody and detected by immunoblotting.
Cell migration and invasion
Boyden Chambers (24-well, 8 mm; Corning, Corning, NY, USA) were used to measure cancer cell migration and invasion. Cells (5 Â 10 4 ) in 100 ml serumfree RPMI 1640 medium were placed in the upper chamber, and 500 ml RPMI 1640 containing 10% fetal bovine serum was added to the lower compartment as a chemoattractant. After incubation for 36 h at 37 1C, cells on the top surface of the membrane were removed by wiping with a cotton swab. The migrated cells on the bottom surface of the membrane were fixed and stained with crystal violet. Cells were counted in four randomly selected fields. The invasion assay was performed in chambers coated with matrigel basement membrane matrix.
DNA methylation analysis
The CpG island DNA methylation status was determined by PCR analysis after bisulfite modification and methylation-specific PCR. The CKIP-1 methylation-specific PCR primers were designed near the transcription start sites in the CpG islands. The following primers were used: CKIP-1 Un Tumor sample evaluation criterion and tumor grading According to the immunoblotting or qRT-PCR analysis, we defined 'ToN' as the condition that CKIP-1 levels in the tumor tissues were dramatically lower than those in the normal tissues. 'TEN' means that the condition of CKIP-1 levels in normal and tumor tissues were similar to each other. 'T4N' represented those CKIP-1 levels in tumor tissues that were higher than those in the normal tissues (T, tumor tissue; N, normal tissue). All colon cancer samples were classified by TNM staging and included 10 cases of stage I, 13 cases of stage II, 12 cases of stage III and 10 cases of stage IV.
Soft agar colony formation assay NCM460 cells were infected with lentivirus as indicated. Six-well plate with 0.6% agar in Dulbecco's modified Eagle's medium as the bottom layer was used for soft-agar colony-formation assay. For each well, 2 Â 10 4 cells suspended in Dulbecco's modified Eagle's medium with 0.3% agarose were plated as top layer and incubated at 37 1C for 2-3 weeks. Colonies were counted under microscope, and the relative number of colonies in experimental group was normalized to control group.
Statistical analysis
Data are shown as the mean±s.d. Statistical comparisons between experimental groups were analyzed using Student's t-tests and one-way analysis of variance, and a two-tailed P-value o0.05 was considered significant. ABBREVIATIONS BMP, bone morphogenetic protein; CKIP-1, casein kinase-2 interacting protein-1; EGFR, epidermal growth factor receptor; GSK3, glycogen synthase kinase-3; mTOR, mammalian target of rapamycin; PI3K, phosphatidylinositol-3-kinase; Smurf1, Smad ubiquitylation regulatory factor-1; TGF-b, transforming growth factor-b.
